$ 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing proprietary drug formulations. These innovative treatments specifically target multiple sclerosis (MS) and various other neurodegenerative disorders. Established in 2016, the company was formerly known as AngioSoma, Inc., rebranding to GlobeStar Therapeutics Corporation in July 2021. Its operations are headquartered in Richland, Washington.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.
Data is available to registered users only